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Abstract
Use of multiple prescribers and pharmacies is a means by which some individuals misuse opioids. Community
characteristics may be important determinants of the likelihood of this phenomenon independent of individual-level
factors. This was a retrospective cohort study with individual-level data derived from California’s statewide prescription drug
monitoring program (PDMP) and county-level socioeconomic status (SES) data derived from the United States Census. Zero-
truncated negative binomial (ZTNB) regression was used to model the association of individual factors (age, gender, drug
schedule and drug dose type) and county SES factors (ethnicity, adult educational attainment, median household income,
and physician availability) with the number of prescribers and the number of pharmacies that an individual used during a
single year (2006). The incidence rates of new prescriber use and new pharmacy use for opioid prescriptions declined across
increasing age groups. Males had a lower incidence rate of new prescriber use and new pharmacy use than females. The
total number of licensed physicians and surgeons in a county was positively, linearly, and independently associated with the
number of prescribers and pharmacies that individuals used for prescription opioids. In summary, younger age, female
gender, and living in counties with more licensed physicians and surgeons were associated with use of more prescribers
and/or more pharmacies for obtaining prescription opioids.
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Introduction
Acute and chronic pain affect over 100 million adults in the
United States [1]. The annual economic cost associated with
chronic pain is estimated at $560–635 billion [1]. Opioid
analgesics have been acknowledged to be an effective treatment
to control moderate to severe pain while simultaneously improving
quality of life [2]. However, the abuse and diversion of these
medications has led to a public health crisis. According to national
surveillance reports in 2009, 35 million US residents aged 12 years
or older reported non-medical use of opioids at least once during
their lifetime [3]. The annual financial cost of prescription opioid
abuse is estimated at about $10 billion [4]. The use of multiple
prescribers (‘‘doctor shopping’’) is one of the most common
methods that drug abusers and dealers employ to obtain
prescription opioids for non-medical use [5,6]. Identifying high-
risk individuals for doctor shopping will play a significant role in
controlling abuse and diversion of prescription opioids.
Illicit drug use and prescription opioid abuse tend to be
intertwined [7]. The National Survey on Drug Use and Health
(NSDUH) established that illicit drug use is associated with several
individual socio-demographic factors. Specifically, illicit drug use is
more common among young adults between 18 and 25 years of
age, males, and high school dropouts [3,8]. By contrast,
prescription opioid abuse related to doctor shopping may be
more consistent with the demographics of the chronic pain
population. Such individuals are more likely to be middle-aged
[9], female, and living below the poverty level [10]. Studying the
demographics of individuals who utilize multiple prescribers will
provide a better picture of who is using this approach to misuse
prescribed opioids.
In recent years, geographic location and interrelated socioeco-
nomic characteristics have been recognized as important factors
that affect overall health. For instance, obesity, metabolic
syndrome, cardiovascular disease, and cancer have all been
associated with the socioeconomic environment independent of
individual factors [11–16]. Residing in socially disadvantaged
neighborhoods (characterized by low education attainment and
poor economic status) was associated with higher exposure to
cocaine in early adolescence [17], increased likelihood of adult
drug use [18–20], or related hospitalization [21], and recidivism
[22,23]. Although these findings reinforce the importance of the
neighborhood social context as a determinant of drug use, most of
them come from studies using either a comprehensive summary
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index [17–19,22] or a measure of only income or poverty
[20,21,23] to represent the level of social economic disadvantage.
Social epidemiologists have questioned this methodology and
proposed examining specific neighborhood socioeconomic deter-
minants instead of overall SES [24]. To our knowledge, no prior
research has focused on neighborhood contextual factors associ-
ated with use of multiple prescribers and/or pharmacies for opioid
prescriptions. The present study will examine the effect of both
individual-level factors (age, gender, and Drug Enforcement
Agency (DEA) scheduling and dose of opioid therapy) and
county-based factors (ethnicity, education attainment, median
household income, and physician availability) on use of multiple
prescribers and/or pharmacies for prescription opioids.
Results
Descriptive statistics
There were 1,087,070 eligible individuals in the CURES
database. However, socioeconomic information was not available
for 18 California counties in US Census data, which led to an
exclusion of 2.8% individuals. The final sample size was
1,057,012.
The number of distinct prescribers that an individual used in
2006 for prescription opioids had a mean of 2.09 and a range of 1
to 158. Approximately 51% (n= 536,408) of individuals obtained
their prescriptions from one prescriber, 45% (n= 476,843) used
two to five prescribers, and 4% (n= 43,761) used six or more
prescribers. The number of pharmacies that an individual used in
2006 for prescription opioids had a mean of 1.75 and a range of 1
to 100. Approximately 59% of individuals used only one
pharmacy (n= 623,357), and 39% (n= 411,704) used two to five
pharmacies, 2% (n= 21,951) used six or more pharmacies in 2006.
Table 1 contains demographics of the study population.
Notably, almost half (46.25%) were between 45 and 64 years of
age, with the majority being female (62.15%). Most individuals
receiving opioids (75.86%) utilized only Schedule III opioids, with
the majority (84.38%) prescribed a low average daily dose of
40 mg or less of morphine-equivalents per day. There was
considerable variation in the distribution of different neighbor-
hood-level socio-economic measures among counties. For exam-
ple, the median (range) was 3.5 (1.7 to 8.1) for percent of the
population who were from multiple ethnic groups, 17 (7.9 to 37.7)
for percent of adult residents who did not graduate from high
school, $53,500 ($37,100 to $81,800) for median household
income, and 3,309 (52 to 26,867) for the number of licensed
physicians and surgeons in a county. Almost four-fifths (78.64%) of
individuals receiving opioids lived in counties where less than 4%
of the population were of two or more races. The majority (93%)
of individuals receiving opioids lived in the 35 counties where less
than 30 percent of residents 25 years of age or older did not
graduate from high school. Three-fifths (60%) of individuals
receiving opioids lived in counties where the median household
income was less than $55,000. Almost two-thirds of individuals
(64.47%) lived in 11 counties where at least 2,000 licensed
physicians and surgeons were available.
Factors associated with the incidence rate of prescriber
use
The multivariable analyses showed that all factors were
significantly (p,0.0001) associated with the incidence rate of
new prescriber use (Tables 2 and 3). The incidence rate of new
prescriber use for opioid prescriptions generally declined across
increasing age groups, although the incidence rates were similar
for the 18–34 and 35–44 year groups. Compared to the individuals
aged 75 years or higher, individuals who were 18–34 years, 35–44
years, 45–64 years and 65–74 years had 2.13 (95% CI: 2.10, 2.15),
2.11 (95% CI: 2.09, 2.14), 1.69 (95% CI: 1.68, 1.71) and 1.23
(95% CI: 1.21, 1.24) times higher incidence rates of new prescriber
use in one calendar year, respectively, when adjusting for other
individual-level and county-based factors. Males had an 8% lower
incidence rate of new prescriber use than females after adjusting
for other factors (adjusted IRR=0.92 (95% CI: 0.91, 0.92)).
Individuals who used only Schedule III opioids had a higher
incidence rate (adjusted IRR=1.11 (95% CI: 1.10, 1.13)) of new
prescriber use than those who solely used Schedule II opioids;
individuals who used both Schedule II and III opioids had the
highest incidence rate (adjusted IRR=3.02 (95% CI: 2.98, 3.06)).
Individuals who received high dose opioid therapy had an adjusted
IRR of 1.38 (95% CI: 1.36, 1.39).
Individuals who resided in counties where less than 4% of the
population belonged to multiple ethnicities had an approximately
5% lower incidence rate of new prescriber use than those who
resided in counties with a more multiethnic mix. Living in counties
where 30% or more of the residents did not graduate from high
school was associated with an 8% higher incidence rate of new
prescriber use than living in other counties. Compared to
individuals located in counties where the median annual
household income was greater than $65,000, those residing in
counties with lower median annual household incomes had either
higher or lower incidence rates of new prescriber use, but the effect
was negligible (all IRRs were close to 1). The total number of
licensed physicians and surgeons in a county was positively,
linearly, and independently associated with the number of
prescribers that individuals used for prescription opioids. Com-
pared to individuals who lived in counties where at least 2000
licensed physicians and surgeons were available, the adjusted IRRs
for those who lived in counties where the number of the licensed
physicians and surgeons were ,500, 500–999, 1000–1999 were
0.89 (95% CI: 0.88, 0.91), 0.95 (95% CI: 0.94, 0.96) and 0.96
(95% CI: 0.95, 0.97), respectively.
Factors associated with the incidence rate of pharmacy
use
The multivariable analyses showed that all factors were
significantly (p ,0.0001) associated with the incidence of
pharmacy use (Tables 4 and 5). The incidence rate of new
pharmacy use also declined across increasing age groups (with the
exception of age group 35–44 years, which had a slightly higher
incidence rate than that of the 18–34 years age group). Compared
to individuals 75 or more years old, individuals who were 18–34
years, 35–44 years, 45–64 years and 65–74 years had 1.75 (95%
CI: 1.73, 1.77), 1.80 (95% CI: 1.77, 1.82), 1.45 (95% CI: 1.44,
1.47) and 1.09 (95% CI: 1.08, 1.11) times higher incidence rates of
new pharmacy use in one calendar year, respectively, when
adjusting for other individual level and county-based factors.
Males had a 6 percent lower incidence rate of new pharmacy use
than females, after adjusting for other factors (adjusted IRR=0.94
(95% CI: 0.93, 0.95)). Individuals who used Schedule III opioids
alone had a higher incidence rate (adjusted IRR=1.25 (95% CI:
1.23, 1.26)) of new pharmacy use than those who used Schedule II
opioids alone; individuals who used both Schedule II and III
opioids had the highest incidence rate (adjusted IRR=2.83 (95%
CI: 2.79, 2.87)). Individuals who received high dose opioid therapy
had a 1.83 (95% CI: 1.81, 1.84) times higher incidence rate of new
pharmacy use than those who did not. Individuals who lived in
counties where less than 4% of the population were comprised of
multiple ethnicities had a higher incidence rate of new pharmacy
use than those who lived in counties with more multiethnic
Factors in Doctor Shopping for Prescribed Opioids
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population. The adjusted IRRs were 1.09 (95% CI: 1.05, 1.13),
1.16 (95% CI: 1.15, 1.17) and 1.03 (95% CI: 1.02, 1.04) when
comparing individuals whose residing county had 1–1.9%, 2–
2.9%, and 3–3.9% multiethnic population to individuals whose
residing county had 4% or more multiethnic population.
Compared to individuals who lived in counties where more than
30% residents did not graduate from high school, the adjusted
IRRs for individuals living in counties where ,10%, 10–19.9%,
and 20–29.9% of residents did not graduate from high school were
0.90 (95% CI: 0.87, 0.93), 1.02 (95% CI: 0.99, 1.05), and 1.15
(95% CI: 1.12, 1.18), respectively. As with prescriber use, the effect
of the median household income on the new pharmacy use was
trivial. Also, the total number of licensed physicians and surgeons
in a county was positively, linearly, and independently associated
with the number of pharmacies that individuals used for
prescription opioids. Compared to individuals who lived in
counties where at least 2000 licensed physicians and surgeons
were available, the adjusted IRRs for individuals who lived in
counties where number of the licensed physicians and surgeons
were ,500, 500–999, 1000–1999 were 0.68 (95% CI: 0.67, 0.70),
0.73 (95% CI: 0.73, 0.74), and 0.78 (95% CI: 0.77, 0.79),
respectively.
Discussion
After combining the California PMP data with US census data,
we examined the associations of individual-level and county-based
factors with use of multiple prescribers and pharmacies for
prescription opioids in California during 2006. Younger age and
female gender were associated with use of more prescribers and
more pharmacies for opioid prescriptions. All county-based factors
(ethnicity, educational attainment, median household income and
physician availability) were significantly associated with use of
multiple prescribers and pharmacies. Among those factors, the
physician availability had a positively linear relationship with the
number of prescribers and pharmacies that patients used in 2006.
Other neighborhood factors such as ethnicity, educational
attainment, and median household income had either small or
inconsistent association, which may be due to influences from
unmeasured factors.
Our findings of the age associations are consistent with the
results from studies on illicit drug use and prescription drug abuse.
The NSDUH demonstrated that the proportion of residents aged
18 or older who used illicit drugs in the past month declined across
increasing age groups, with the peak incidence rate in the 18–25
year group [3]. Similarly, White et al. found that the odds of being
involved in prescription opioid abuse declined with age, with a
peak in the 18–24 year group [36]. Interestingly, our study
revealed that individuals in the 18–34 and 35–44 year groups had
similar incidence rates of new prescriber use and new pharmacy
use. The similarity between the two age groups may be explained
by the high incidence of middle-aged individuals susceptible to
chronic pain [9]. Rather than ascribe the behavior of any of these
cohorts to abuse, perhaps the supplementary prescribers were
dissociated from the primary prescriber, or were associates
covering the provider. Moreover, some patients might have visited
additional prescribers while seeking pain relief or have used
additional pharmacies for legitimate reasons. Unfortunately, this
cannot be verified and remains a limitation of the secondary data
analysis.
Multiple studies have consistently found that illicit drug use is
higher among males [37]. However, findings on gender effects
from studies involving prescription opioid abuse have been mixed.
For instance, White et al. found that males had 70% higher odds
of being prescription opioid abusers than females [36]. However,
they included heroin abusers, thereby biasing their results towards
a gender distribution among illicit drug users [36]. Another study
examined predictors of opioid misuse in individuals with chronic
pain and did not find gender a risk factor for prescription opioid
misuse [38]. In that study, individuals were derived from referrals
within an academic internal medicine practice, which may not be
Table 1. Characteristics of the study population from the
CURES, 2006.
Factor
Overall
individuals
(N=1,057,012)
Individual characteristics
Age (years)
18–34 12.49%
35–44 16.55%
45–64 46.25%
65–74 12.34%
75–100 12.37%
Gender
Male 37.85%
Female 62.15%
Drug schedule
only Schedule II 6.93%
only Schedule III 75.86%
both Schedule II and Schedule III 17.21%
Dose type
#40 mg/day 84.38%
.40 mg/day 15.62%
County characteristics
Percent of multiracial population
1–1.9 1.50%
2–2.9 34.72%
3–3.9 42.41%
4+ 21.36%
Percent of residents who did not graduate from high
school
0.0–9.9 3.64%
10.0–19.9 49.34%
20.0–29.9 43.42%
30.0+ 3.61%
Median annual household income ($10,000)
3.5–4.4 14.65%
4.5–5.4 44.63%
5.5–6.4 17.37%
$6.5 23.35%
Number of licensed physicians and surgeons
,500 11.31%
500–999 12.13%
1000–1999 12.08%
$2000 64.47%
doi:10.1371/journal.pone.0046246.t001
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representative of other settings [38]. Hall et al. found males were
more likely to be involved in prescription drug diversion and
females were more likely to use 5 or more prescribers for
prescription drug [39]. Simoni-Wastila conducted two studies
using data from National Household Survey on Drug Abuse
(http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1448242/
?tool = pubmed - r1NHSDA) and found females were 1.5–2 times
more likely to experience problem use of prescribed opioid
analgesics [40,41]. Moreover, data from substance treatment
centers suggests that females were more likely than males to report
abuse of any prescription opioid (15.4% females vs. 11.1% males,
p,0.001) [42], which is consistent with this study’s findings.
Our results revealed that individuals who used both Schedule II
and III opioids visited multiple prescribers and multiple pharma-
cies more often than those who used only one DEA opioid
schedule. It is conceivable that these individuals had more severe
pain or opioid tolerance, necessitating seeing more prescribers and
pharmacies to obtain greater amounts of opioids. Without detailed
information on the indication for each prescription, it is not
possible to infer a causal relationship between opioid utilization
(drug schedule and/or dose type of therapy) and the multiple
prescribers and/or pharmacies use – another limitation of a
secondary data analysis.
Our data showed that the most robust county-level factor was
the physician availability. The positive linear association between
the number of available physicians or surgeons in patients’
residency county and the number of prescribers and pharmacies
that patients used in a year is consistent with another study
whereby the number of prescribers per 1,000 people in a county
was independently and positively associated with insurance claim
Table 2. Adjusted incidence rate ratios and 95% confidence
intervals (CI) from multivariable ZTNB regression model of
individual characteristics for prescriber use to obtain
prescription opioids in California in 2006.
Factor Adjusted IRR (95% CI) P-value*
Age (years) ,0.0001
18–34 2.13 (2.10, 2.15)
35–44 2.11 (2.09, 2.14)
45–64 1.69 (1.68, 1.71)
65–74 1.23 (1.21, 1.24)
75–100 1.00
Gender ,0.0001
Male 0.92 (0.91, 0.92)
Female 1.00
Drug schedule ,0.0001
only Schedule II 1.00
only Schedule III 1.11 (1.10, 1.13)
both Schedule II and Schedule III 3.02 (2.98, 3.06)
Dose type ,0.0001
#40 mg/day 1.00
.40 mg/day 1.38 (1.36, 1.39)
Note. Factors in the table adjusted each other through this multivariable ZTNB
regression model.
*p-value from F-test for assessing the effect of a factor in multivariable analysis.
doi:10.1371/journal.pone.0046246.t002
Table 3. Adjusted incidence rate ratios and 95% confidence intervals (CI) from multivariable ZTNB regression model of county
characteristics for prescriber use to obtain prescription opioids in California in 2006.
Factor Adjusted IRR (95% CI) P-value*
Percent of multiracial population ,0.0001
1–1.9 0.92 (0.89, 0.95)
2–2.9 0.96 (0.95, 0.97)
3–3.9 0.96 (0.95, 0.96)
4+ 1.00
Percent of residents who did not graduate from high school ,0.0001
0.0–9.9 0.92 (0.89, 0.94)
10.0–19.9 0.92 (0.90, 0.95)
20.0–29.9 0.92 (0.90, 0.94)
30.0+ 1.00
Median annual household income ,0.0001
35,000–44,999 0.98 (0.96, 0.99)
45,000–54,999 0.97 (0.96, 0.98)
55,000–64,999 1.01 (1.00, 1.02)
65,000+ 1.00
Number of licensed physicians and surgeons ,0.0001
,500 0.89 (0.88, 0.91)
500–999 0.95 (0.94, 0.96)
1,000–1,999 0.96 (0.95, 0.97)
$2,000 1.00
Note. Factors in the table adjusted each other through this multivariable ZTNB regression model.
*p-value from F-test for assessing the effect of a factor in multivariable analysis.
doi:10.1371/journal.pone.0046246.t003
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rates for opioids [43]. One possible explanation for this finding is
that the availability of more prescribers allows legitimate
individuals to solicit more physicians in controlling their under-
treated pain while simultaneously allowing abusers the opportunity
to enlist more prescribers in their efforts to obtain prescription
opioids for nefarious purposes. We speculated that a county with
higher physician availability may also have higher pharmacy
availability, which likewise may explain the positive association
between the physician availability and multiple pharmacies use.
We were unable to account for the possibility that individuals went
to adjacent counties for opioid prescriptions, so the association of
the physician availability in a county may have been underesti-
mated. It should be emphasized that, due to the inability to
distinguish abusers from legitimate patients, it was not possible for
this study to explore the association between physician availability
and drug abuse.
Based on previous research on illicit drug use, we hypothesized
that regions with more multiethnic residents, a higher proportion
of high school dropouts, and lower median household income
would be associated with a higher incidence rate of new prescriber
use or new pharmacy use. However, the direction of the
association between ethnicity, educational attainment, median
household income and use of new prescribers or pharmacies was
variable and inconsistent. Studies have indicated that illicit drug
use is associated with multiple factors, such as an individual’s
psychological factors [44], socioeconomic status [3], the drug use
in individuals’ social network [45], and neighborhood social
disorder (i.e., low informal social control) [46–48] or disadvantage
(i.e., low educational attainment and poor economic status)
[18,23,45]. The same factors may affect multiple prescribers and
Table 5. Adjusted incidence rate ratios and 95% confidence intervals (CI) from multivariable ZTNB regression model of county
characteristics for pharmacy use to obtain prescription opioids in California in 2006.
Factor Adjusted IRR (95% CI) P-value*
Percent of multiracial population ,0.0001
1–1.9 1.09 (1.05, 1.13)
2–2.9 1.16 (1.15, 1.17)
3–3.9 1.03 (1.02, 1.04)
4+ 1.00
Percent of residents who did not graduate from high school ,0.0001
0.0–9.9 0.90 (0.87, 0.93)
10.0–19.9 1.02 (0.99, 1.05)
20.0–29.9 1.15 (1.12, 1.18)
30.0+ 1.00
Median annual household income ,0.0001
35,000–44,999 0.97 (0.95, 0.99)
45,000–54,999 0.98 (0.97, 0.99)
55,000–64,999 1.02 (1.01, 1.03)
65,000+ 1.00
Number of licensed physicians and surgeons ,0.0001
,500 0.68 (0.67, 0.70)
500–999 0.73 (0.73, 0.74)
1,000–1,999 0.78 (0.77, 0.79)
$2,000 1.00
Note. Factors in the table adjusted each other through this multivariable ZTNB regression model.
*p-value from F-test for assessing the effect of a factor in multivariable analysis.
doi:10.1371/journal.pone.0046246.t005
Table 4. Adjusted incidence rate ratios and 95% confidence
intervals (CI) from multivariable ZTNB regression model of
individual characteristics for pharmacy use to obtain
prescription opioids in California in 2006.
Factor Adjusted IRR (95% CI) P-value*
Age (years) ,0.0001
18–34 1.75 (1.73, 1.77)
35–44 1.80 (1.77, 1.82)
45–64 1.45 (1.44, 1.47)
65–74 1.09 (1.08, 1.11)
75–100 1.00
Gender ,0.0001
Male 0.94 (0.93, 0.95)
Female 1.00
Drug schedule ,0.0001
only Schedule II 1.00
only Schedule III 1.25 (1.23, 1.26)
both Schedule II and Schedule III 2.83 (2.79, 2.87)
Dose type ,0.0001
#40 mg/day 1.00
.40 mg/day 1.83 (1.81, 1.84)
Note. Factors in the table adjusted each other through this multivariable ZTNB
regression model.
*p-value from F-test for assessing the effect of a factor in multivariable analysis.
doi:10.1371/journal.pone.0046246.t004
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pharmacies utilization among prescription opioid users. Due to
privacy considerations, only limited individual information was
available in the California PMP database, precluding more
thorough control of confounding and potentially affecting study
validity. Future research with more detailed individual information
is needed to complement this study. We believe, however, that
such unmeasured factors did not substantially affect the association
estimates of age, gender, and the number of licensed physicians
and surgeons in a county because they should not act as
confounders for these variables.
Another limitation of this study was that we had no control
over data quality. However, because provision of data is
legislatively mandated with penalties for noncompliance, we
suspect that the data is of high quality with respect to accuracy
and completeness.
Despite the limitations enumerated above, this study is the first
to estimate the county-level contextual effect on use of multiple
prescribers or pharmacies to obtain pain relieving opiates. This
population-based study had a very large sample size, permitting
high precision of the incidence rate ratio estimates. Using a
mandated collection source avoided underreporting bias, a
limitation of self-reported studies. The study population was all
outpatient prescription opioid users in California except those
obtaining prescription opioids in federal facilities (i.e., facilities
associated the Department of Defense or the Department of
Veterans Affairs), which minimized the random error of the
results.
In summary, our results show that use of multiple prescribers
and/or pharmacies to obtain prescription opioids is more
common among females and individuals of young to middle
ages (18–45 years). Physician availability in a county is positively
associated with the number of prescribers or pharmacies that
patients used for prescription opioids. Counties with more than
2,000 licensed physicians and surgeons should receive additional
scrutiny to prevent multiple provider and pharmacy episodes.
Law enforcement authorities would be wise to concentrate efforts
on large metropolitan areas. Whether these episodes represent
justifiable activities by patients or characterize abuse and
diversion cannot be determined from a cursory examination or
generalization from epidemiologic data. For the provider, clinical
observation, combined with judicious use of PMP data, are
necessary to make individualized decisions in the case of a patient
seeking opioids.
Methods
Study population
This retrospective cohort study used data from the California
PDMP, the Controlled Substance Utilization Review and
Evaluation System (CURES). This database is operated under
the auspices of the California Department of Justice. The system
was converted from a paper-based to an electronic controlled
substance surveillance system in 1998, about sixty years after
California established the first PDMP in the nation. Pharmacists
input the drug name, quantity, dosage, and date of the
transaction at the point of disbursement into CURES. In
addition, the patients’ name, date of birth, gender, and address
are transmitted, as are the prescriber and pharmacy identities
with the DEA registration numbers. To ensure confidentiality
and anonymity of the information obtained for this study, the
CURES database underwent de-identification as described in one
of our previous study [25]. Individuals were included in the study
if they had at least one opioid prescription in each of three years,
2005 through 2007 (Table 6). By incorporating three consecutive
years, with only prescriptions from 2006 being utilized for data
analysis, each patient was assured of one person-year exposure in
which they were at risk of using multiple prescribers or using
multiple pharmacies. Data was excluded if a prescription was: (1)
incomplete with respect to the age, gender and prescriber
information; (2) implausible, e.g., a duplicate prescription with
the same formulation recorded for the same time period; (3) a
commercial transaction whereby the prescription was written for
more than 700 pills or 50 patches in a given 30-day period (based
on personal communication with the manager of the CURES
database in the California Department of Justice); (4) for
medications not suggestive of standard delivery systems employed
by most chronic pain individuals (e.g., rectal suppositories,
intravenous preparations, syrups, solutions, etc.); (5) for use of
medication by age groups normally not associated with chronic
pain or obtaining medications through office use interactions, i.e.,
children under the age of 18 and adults over 100 years of age,
respectively.
The Institutional Review Board of the University of California
at Davis and the Veterans Administration Northern California
Health Care System Research and Development Committee
granted approvals to conduct this research.
Dependent regression variables
Dependent variables included the number of distinct doctors
and the number of distinct pharmacies that an individual used for
all his/her opioid prescriptions obtained during January 1, 2006
through December 31, 2006.
Individual-level factors (age, gender, drug schedule and
dose type of opioid therapy)
Each individual’s age and gender was tallied. Stratification into
five age groups was performed in the manner of previous
investigations [26]. The categorization was: 18–34, 35–44, 45–
64, 65–74, and 75–100 years of age.
The DEA controlled substance schedule was used to stratify
individuals into three groups: those who used only Schedule II
opioids, those who used only Schedule III opioids, and those who
used both Schedule II and III opioids in calendar year 2006.
The association between individuals’ rate of opioid consumption
and their use of multiple prescribers and pharmacies was
examined using a calculated average daily dose. This quantity
was defined as high dose therapy if the average daily dose was
greater than 40 mg of morphine-equivalents per day. A low dose
was characterized as 40 mg or less of morphine-equivalents per
day. This cutoff point was related to the practice of providing a
maximum of eight hydrocodone or oxycodone pills in combina-
tion with acetaminophen. The limit on so-called ‘‘weak opioids’’,
which in 2006 was 4,000 mg of acetaminophen (that also included
40 mg of an opioid), was designed to prevent toxicity from this
otherwise over-the-counter analgesic [27,28]. More than 40 mg
per day of an opioid often involved the addition of a sustained-
release preparation with commensurate increases in dosing. The
average daily opioid dose was computed using the sum of
morphine-equivalents (product of strength, quantity, and an
equianalgesic conversion factor [29]) divided by the duration of
prescribing. The latter was calculated as the interval between an
individual’s first and last opioid prescriptions in 2006 plus an
estimate of the duration of his/her last prescription utilizing the
‘‘last observation carry forward’’ method [30,31]. Further details
of this methodology were discussed in our previous publication
[25].
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County-based factors (ethnicity, education, income and
physician availability)
The individual level data was linked to the county-specific
survey data obtained from the 2006 US Census Database [32]. We
considered four social domains of California counties: ethnicity,
educational attainment, economic status and medical resource
availability as discussed below:
1. Ethnicity: the percent of the total population in each county in
2006 that self-reported his/her heritage was derived from two
or more ethnic groups. This categorization was selected to
measure an ethnicity effect inasmuch as the highest rates of
past month illicit drug use generally occur among persons
reporting themselves to be derived from two or more ethnic
groups [33,34].
2. Educational attainment: the percent of people 25 years and
over in each county in 2006 who did not complete high school.
3. Economic status: the median annual household income in each
county in 2006.
4. Medical resource availability: the number of licensed physi-
cians and surgeons in each county in 2006, derived from Rand
California Community Statistics Database [35].
Statistical analysis
The two outcomes, number of opioid prescribers and number of
pharmacies, were count variables without zero in their range, i.e.,
all individuals used at least one prescriber and one pharmacy.
Therefore, a zero-truncated count model was chosen for the
analysis. The initial data exploration showed that the relationship
between each of the continuous independent variable and the log
of outcome variables was non linear, so all continuous indepen-
dent variables were polychotomized into categorical variables.
Univariable analysis showed the existence of over-dispersion for
the outcome variables, so the ZTNB regression model was used as
the primary analysis model. PROC NLMIXED in Statistical
Analysis System (SAS) was used for the regression analyses and
CONTRAST statements in the procedure were used to examine
the effect of each factor. Only variables with statistically significant
effects in the univariable analysis were included in the final
multivariable model. The adjusted incidence rate ratios (adjusted
IRR) and 95% confidence intervals (95% CI) from the multivar-
iable model were separately presented for the two outcome
variables. All of the analyses were carried out with SAS v9.2 (SAS
Institute Inc., Cary, NC, USA).
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